PRESS RELEASE published on 06/20/2025 at 19:10, 1 year 2 months ago Inside Information / Other news releases CARMAT launches a donation campaign to address critical financial situation and risk of insolvency. The initiative aims to secure urgent funding for its innovative total artificial heart Financial Situation CARMAT Artificial Heart Donation Campaign Risk Of Insolvency
PRESS RELEASE published on 06/20/2025 at 19:10, 1 year 2 months ago Informations privilégiées / Autres communiqués CARMAT lance une campagne de dons pour assurer son financement et ses activités face à un risque de cessation des paiements. Aeson® : cœur artificiel avancé par la medtech française Financement MedTech CARMAT Aeson® Campagne De Dons
BRIEF published on 06/04/2025 at 17:50, 1 year 3 months ago CARMAT : Modalités pour l'Assemblée Générale du 26 Juin 2025 Assemblée Générale Risques Financiers Vote À Distance CARMAT Coeur Artificiel
BRIEF published on 06/04/2025 at 17:50, 1 year 3 months ago CARMAT: Terms and conditions for the General Meeting of June 26, 2025 General Assembly Remote Voting CARMAT Artificial Heart Financial Risks
PRESS RELEASE published on 06/04/2025 at 17:45, 1 year 3 months ago Modalités de mise à disposition des documents préparatoires à l'AG CARMAT annonce son assemblée générale mixte le 26 juin 2025. Participation et vote possibles à distance. Consultation des documents et modalités sur le site de la société Assemblée Générale Documents Préparatoires Vote À Distance CARMAT Thérapeutique
BRIEF published on 06/02/2025 at 07:05, 1 year 3 months ago CARMAT makes its first sales of artificial hearts in Israel CARMAT European Union Israel Aeson® Locations
BRIEF published on 06/02/2025 at 07:05, 1 year 3 months ago CARMAT réalise ses premières ventes de cœurs artificiels en Israël Union Européenne CARMAT Israel Aeson® Implantations
PRESS RELEASE published on 06/02/2025 at 07:00, 1 year 3 months ago Informations privilégiées / Autres communiqués CARMAT annonce les premières implantations commerciales de son cœur artificiel Aeson en dehors de l'Union européenne, avec deux réalisations en Israël CARMAT Coeur Artificiel Israel Aeson Implantations Commerciales
BRIEF published on 04/09/2025 at 17:50, 1 year 5 months ago CARMAT réalise de solides résultats au premier trimestre 2025 CARMAT T1 2025 Implants Aeson® Essai EFICAS Discussions De La FDA
BRIEF published on 04/09/2025 at 17:50, 1 year 5 months ago CARMAT Achieves Strong Q1 2025 Results CARMAT Q1 2025 FDA Discussions Aeson® Implants EFICAS Trial
Published on 09/12/2026 at 02:35, 11 hours 37 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 12 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 7 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 47 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 12 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 42 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 57 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 2 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 28 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 57 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
